Surgery Doctors in Olathe, KS Accepting Medicare

8 Surgery doctors found. Showing 1 - 8

Anne Catherine Rhoads, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 11400 S Parkwood Dr, Olathe, KS 66061 Phone: 913-894-5261

Craig A Anderson, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20375 W 151st St, Suite 463, Olathe, KS 66061 Phone: 913-782-8577    Fax: 913-782-2616

John B Moore Iv, MD Surgery - Plastic and Reconstructive Surgery Medicare: Not Enrolled in Medicare Practice Location: 20375 W 151st St, Suite 370, Olathe, KS 66061 Phone: 913-782-0707    Fax: 913-782-5813

Michael P Davoren, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20375 W 151st St, Suite 463, Olathe, KS 66061 Phone: 913-782-8577    Fax: 913-782-2616

Bradley W Storm, MD Surgery - Surgery of the Hand Medicare: Accepting Medicare Assignments Practice Location: 20375 W 151st St #370, Premier Plastic Surgery, Olathe, KS 66061 Phone: 913-782-0707    Fax: 913-782-5813

Dr. Curtis Trigueiro Selser, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20333 W 151st St, Olathe, KS 66061 Phone: 913-791-4291

Elizabeth K Long, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20375 W 151st St, Suite 463, Olathe, KS 66061 Phone: 913-782-8577    Fax: 913-782-2616

Harlan L Opie, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20375 W 151st St, Suite463, Olathe, KS 66061 Phone: 913-782-8577    Fax: 913-782-2616

News Archive

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

Oxford University performs second phase of experimental Ebola vaccine trial

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.

Expanding risk assessment parameters improves prediction of waitlist mortality for liver transplants

The top priority in the field of transplantation is to ensure that donor organs are allocated to the patients with the greatest need.

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

Researchers develop novel tool to predict person's chance of survival after gunshot wounds

Researchers have developed a first-of-its-kind tool to help predict a person's chance of survival after a gunshot wound in the head or other penetrating injury, according to a new study published in the October 26, 2016, online issue of Neurology, a medical journal of the American Academy of Neurology.

Read more Medical News

› Verified 2 days ago